129 related articles for article (PubMed ID: 28203164)
41. Primary Cutaneous Mucinous Carcinoma with Extramammary Paget's Disease: Eccrine or Apocrine?
Oh SJ; Kim YO
J Pathol Transl Med; 2018 Jul; 52(4):238-242. PubMed ID: 29366305
[TBL] [Abstract][Full Text] [Related]
42. Denosumab-related osteonecrosis of the jaw: a case report and management based on pharmacokinetics.
You Tm; Lee KH; Lee SH; Park W
Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Nov; 120(5):548-53. PubMed ID: 26337218
[TBL] [Abstract][Full Text] [Related]
43. Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.
Yamagishi T; Kawashima H; Ogose A; Ariizumi T; Sasaki T; Hatano H; Hotta T; Endo N
PLoS One; 2016; 11(5):e0154680. PubMed ID: 27163152
[TBL] [Abstract][Full Text] [Related]
44. Apocrine adenocarcinoma of the eyelid: case series and review.
Figueira EC; Danks J; Watanabe A; Khong JJ; Ong L; Selva D
Ophthalmic Plast Reconstr Surg; 2013; 29(6):417-23. PubMed ID: 24217473
[TBL] [Abstract][Full Text] [Related]
45. In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid.
Shibuya I; Takami M; Miyamoto A; Karakawa A; Dezawa A; Nakamura S; Kamijo R
Pathol Oncol Res; 2019 Jan; 25(1):409-419. PubMed ID: 29159783
[TBL] [Abstract][Full Text] [Related]
46. Primary apocrine adenocarcinoma of scrotum suspected as urothelial carcinoma metastasis: A clinical and pathological dilemma.
Huang S; Frydenberg M; Pham A; Grummet JP
Urol Ann; 2015; 7(1):97-9. PubMed ID: 25657556
[TBL] [Abstract][Full Text] [Related]
47. Preoperative carboplatin and paclitaxel-based chemoradiotherapy for esophageal carcinoma: results of a modified CROSS regimen utilizing radiation doses greater than 41.4 Gy.
Nabavizadeh N; Shukla R; Elliott DA; Mitin T; Vaccaro GM; Dolan JP; Maggiore RJ; Schipper PH; Hunter JG; Thomas CR; Holland JM
Dis Esophagus; 2016 Aug; 29(6):614-20. PubMed ID: 26043837
[TBL] [Abstract][Full Text] [Related]
48. Giant Cell Lesions of the Maxillofacial Skeleton Express RANKL by RNA In Situ Hybridization Regardless of Histologic Pattern.
Stagner AM; Sajed DP; Nielsen GP; Ebb DH; Faquin WC; Chebib I; Rivera MN; Ting DT; Resnick CM; Peacock ZS; Kaban LB; Deshpande V
Am J Surg Pathol; 2019 Jun; 43(6):819-826. PubMed ID: 30998511
[TBL] [Abstract][Full Text] [Related]
49. Clinical outcome of recurrent giant cell tumor of the extremity in the era before molecular target therapy: the Japanese Musculoskeletal Oncology Group study.
Takeuchi A; Tsuchiya H; Ishii T; Nishida Y; Abe S; Matsumine A; Kawai A; Yoshimura K; Ueda T
BMC Musculoskelet Disord; 2016 Jul; 17():306. PubMed ID: 27448567
[TBL] [Abstract][Full Text] [Related]
50. The RANK-RANKL axis: an opportunity for drug repurposing in cancer?
Peters S; Clézardin P; Márquez-Rodas I; Niepel D; Gedye C
Clin Transl Oncol; 2019 Aug; 21(8):977-991. PubMed ID: 30656607
[TBL] [Abstract][Full Text] [Related]
51. [Therapeutic agents for disorders of bone and calcium metabolism--Denosumab, a fully human monoclocal antibody-targeting RANKL as a therapy for cancer-induced bone diseases].
Mera K; Ito K
Clin Calcium; 2007 Jan; 17(1):37-46. PubMed ID: 17211092
[TBL] [Abstract][Full Text] [Related]
52. Cutaneous adnexal carcinoma with apocrine differentiation.
Prasad V; Kao WH; Kao GF
Cutis; 2016 Dec; 98(6):E16-E19. PubMed ID: 28099545
[TBL] [Abstract][Full Text] [Related]
53. [Comparative analysis of clinical efficacies between induction chemotherapy and surgery combined with radiotherapy or concurrent chemoradiotherapy in advanced hypopharyngeal carcinoma].
Li ZD; Lu T
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2018 Dec; 53(12):918-924. PubMed ID: 30585004
[No Abstract] [Full Text] [Related]
54. Denosumab Therapy in the Management of Aneurysmal Bone Cysts: A Comprehensive Literature Review.
Alhumaid I; Abu-Zaid A
Cureus; 2019 Jan; 11(1):e3989. PubMed ID: 30972268
[TBL] [Abstract][Full Text] [Related]
55. Treatment of a skull-base giant cell tumor with endoscopic endonasal resection and denosumab: case report.
Goto Y; Furuno Y; Kawabe T; Ohwada K; Tatsuzawa K; Sasajima H; Hashimoto N
J Neurosurg; 2017 Feb; 126(2):431-434. PubMed ID: 27177173
[TBL] [Abstract][Full Text] [Related]
56. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.
Yonezawa N; Murakami H; Kato S; Takeuchi A; Tsuchiya H
Eur Spine J; 2017 May; 26(Suppl 1):236-242. PubMed ID: 28396950
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant carboplatin and paclitaxel after concurrent cisplatin and radiotherapy in patients with locally advanced cervical cancer.
Yavas G; Yavas C; Sen E; Oner I; Celik C; Ata O
Int J Gynecol Cancer; 2019 Jan; 29(1):42-47. PubMed ID: 30640682
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic Potential of Denosumab in Patients With Lung Cancer: Beyond Prevention of Skeletal Complications.
De Castro J; García R; Garrido P; Isla D; Massuti B; Blanca B; Vázquez J
Clin Lung Cancer; 2015 Nov; 16(6):431-46. PubMed ID: 26264596
[TBL] [Abstract][Full Text] [Related]
59. Case report: differential diagnosis between primary cutaneous apocrine adenocarcinoma versus extramammary or metastatic breast adenocarcinoma.
Toledo-Pastrana T; Llombart-Cussac B; Traves-Zapata V; Requena-Caballero C; Sanmartín-Jimenez O; Angeles-Sales M; Cabezas M; Guillén-Barona C
Am J Dermatopathol; 2014 Oct; 36(10):e175-8. PubMed ID: 23863550
[TBL] [Abstract][Full Text] [Related]
60. Objective tumor response to denosumab in patients with giant cell tumor of bone: a multicenter phase II trial.
Ueda T; Morioka H; Nishida Y; Kakunaga S; Tsuchiya H; Matsumoto Y; Asami Y; Inoue T; Yoneda T
Ann Oncol; 2015 Oct; 26(10):2149-54. PubMed ID: 26205395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
